Program
Ritonavir
Also written as “ritonavir”, “PF-07321332/ritonavir” and “RTV”.
Its studies are mostly in HIV Infections · Hepatitis C · COVID-19 · Hepatitis C, Chronic · Acquired Immunodeficiency Syndrome, led by 6 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 320 open or running | phase 4since Sep 28, 2007 | Mar 19, 2003 | none ahead |
| Hoffmann-La Roche | 230 open or running | phase 3since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Bristol-Myers Squibb | 190 open or running | phase 4since Oct 3, 2006 | May 6, 2002 | none ahead |
| Abbott | 60 open or running | phase 3since May 31, 2002 | Nov 2, 1999 | none ahead |
| eiger-biopharmaceuticals | 20 open or running | phase 3since Oct 18, 2018 | Nov 15, 2016 | none ahead |
| ppd-development-lp | 10 open or running | phase 3since Oct 10, 2000 | Oct 10, 2000 | none ahead |
Also a collaborator on its studies: almedis, Pfizer, tibotec-therapeutics-a-division-of-ortho-biotech-products-l-, tibotec-pharmaceutical-limited, Shionogi and trimeris.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 27 studies since Aug 16, 2006.
- May 3, 2012Phase 1 study in Healthy VolunteerHoffmann-La Roche · NCT01591850 · 51 enrolled · United States
- Jun 6, 2012Phase 1 study in HIV InfectionsHoffmann-La Roche · NCT01638650 · 23 enrolled · United Kingdom
- Jun 22, 2012Phase 2 study in Hepatitis C, ChronicHoffmann-La Roche · NCT01628094 · 110 enrolled · United States, Australia, Germany and more
- Sep 21, 2012Phase 4 study in HIV, PediatricBristol-Myers Squibb · NCT01691794 · 108 enrolled · United States, Argentina, Brazil and more
- Jun 6, 2014Phase 1 study in Hepatitis CBristol-Myers Squibb · NCT02159352 · 49 enrolled · United States
- Jul 18, 2014Phase 1 study in HealthyBoehringer Ingelheim · NCT02195466 · 20 enrolled
- Aug 26, 20143 phase 1 studies in HealthyBoehringer Ingelheim · NCT02227017, NCT02226991, NCT02226978
- Aug 28, 2014Phase 2 study in HIV InfectionsBoehringer Ingelheim · NCT02229760 · 3 enrolled
- Sep 11, 20142 phase 2 studies in HIV InfectionsBoehringer Ingelheim · NCT02239835, NCT02251223
- Sep 18, 201415 phase 1 studiesBoehringer Ingelheim · NCT02245451, NCT02245438, NCT02245269 and 12 more
- Oct 2, 20143 phase 1 studies in HealthyBoehringer Ingelheim · NCT02257021, NCT02256826, NCT02256774
- Dec 17, 2014Phase 1 study in Healthy VolunteerHoffmann-La Roche · NCT02321384 · 100 enrolled · Netherlands
- Nov 15, 2016eiger-biopharmaceuticals's first study: phase 2 study in Hepatitis D, ChronicNew to eiger-biopharmaceuticalseiger-biopharmaceuticals · NCT02968641
- Oct 18, 2018Phase 3 study in Hepatitis Deiger-biopharmaceuticals · NCT03719313 · 407 enrolled · United States, Belgium, Bulgaria and more
TargetBeta
“Human immunodeficiency virus type 1 protease inhibitor; Cytochrome P450 3A inhibitor”ChEMBL 37, by rule
Studies
The newest 60 of 83 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT03719313Hepatitis D · United States, Belgium, Bulgaria and more | 3 | Completed | eiger-biopharmaceuticals | Oct 6, 2022 | 407 |
| NCT02968641Hepatitis D, Chronic | 2 | Withdrawn | eiger-biopharmaceuticals | Feb 12, 2021 | 0 |
| NCT02321384Healthy Volunteer · Netherlands | 1 | Terminated | Hoffmann-La Roche | Nov 26, 2015 | 100 |
| NCT02257021Healthy | 1 | Completed | Boehringer Ingelheim | May 2005 | 34 |
| NCT02256826Healthy | 1 | Completed | Boehringer Ingelheim | Jun 2005 | 34 |
| NCT02256774Healthy | 1 | Completed | Boehringer Ingelheim | May 2005 | 51 |
| NCT02253953Healthy | 1 | Completed | Boehringer Ingelheim | Dec 2003 | 62 |
| NCT02253914Healthy | 1 | Completed | Boehringer Ingelheim | Dec 2004 | 100 |
| NCT02253901Healthy | 1 | Completed | Boehringer Ingelheim | May 2005 | 33 |
| NCT02253875Healthy | 1 | Completed | Boehringer Ingelheim | Feb 2006 | 15 |
| NCT02253862Healthy | 1 | Completed | Boehringer Ingelheim | Mar 2006 | 17 |
| NCT02253836Healthy | 1 | Completed | Boehringer Ingelheim | Jul 2005 | 21 |
| NCT02253797Healthy | 1 | Completed | Boehringer Ingelheim | Jul 2003 | |
| NCT02251223HIV Infections | 2 | Completed | Boehringer Ingelheim | Feb 2002 | 208 |
| NCT02251158Healthy | 1 | Completed | Boehringer Ingelheim | Dec 2003 | 30 |
| NCT02251145Healthy | 1 | Completed | Boehringer Ingelheim | Jun 2002 | 49 |
| NCT02251119Healthy | 1 | Completed | Boehringer Ingelheim | Jan 2003 | 24 |
| NCT02259855Hepatic Insufficiency | 1 | Completed | Boehringer Ingelheim | Oct 1, 2008 | 36 |
| NCT02245451Healthy | 1 | Completed | Boehringer Ingelheim | Feb 2005 | 15 |
| NCT02245438Healthy | 1 | Terminated | Boehringer Ingelheim | Jun 2002 | 52 |
| NCT02245269Healthy | 1 | Completed | Boehringer Ingelheim | Oct 2003 | 23 |
| NCT02244190Healthy | 1 | Completed | Boehringer Ingelheim | May 2008 | 32 |
| NCT02239835HIV Infections | 2 | Terminated | Boehringer Ingelheim | Nov 2001 | 79 |
| NCT02229760HIV Infections | 2 | Terminated | Boehringer Ingelheim | Sep 2007 | 3 |
| NCT02227017Healthy | 1 | Completed | Boehringer Ingelheim | Apr 2006 | 35 |
| NCT02226991Healthy | 1 | Completed | Boehringer Ingelheim | Jul 2006 | 34 |
| NCT02226978Healthy | 1 | Completed | Boehringer Ingelheim | May 2007 | 29 |
| NCT02195466Healthy | 1 | Completed | Boehringer Ingelheim | Jul 2003 | 20 |
| NCT02159352Hepatitis C · United States | 1 | Completed | Bristol-Myers Squibb | Jul 2014 | 49 |
| NCT01691794HIV, Pediatric · United States, Argentina, Brazil and more | 4 | Completed | Bristol-Myers Squibb | Oct 31, 2014 | 108 |
| NCT01628094Hepatitis C, Chronic · United States, Australia, Germany and more | 2 | Completed | Hoffmann-La Roche | Nov 2013 | 110 |
| NCT01638650HIV Infections · United Kingdom | 1 | Completed | Hoffmann-La Roche | Jun 2012 | 23 |
| NCT01591850Healthy Volunteer · United States | 1 | Completed | Hoffmann-La Roche | Nov 2011 | 51 |
| NCT01592318Healthy Volunteer · New Zealand | 1 | Completed | Hoffmann-La Roche | Jun 2012 | 42 |
| NCT01592305Healthy Volunteer · United States | 1 | Completed | Hoffmann-La Roche | Jun 2012 | 40 |
| NCT01588002Healthy Volunteer · United States | 1 | Completed | Hoffmann-La Roche | Jun 2012 | 40 |
| NCT01519336Healthy Volunteer · United States | 1 | Completed | Hoffmann-La Roche | Mar 2012 | 40 |
| NCT01531647Healthy Volunteer · United States | 1 | Completed | Hoffmann-La Roche | Mar 2012 | 20 |
| NCT01514968Healthy Volunteer · United States | 1 | Completed | Hoffmann-La Roche | Feb 2012 | 18 |
| NCT01483742Hepatitis C, Chronic · United States, Australia, Canada and more | 2 | Completed | Hoffmann-La Roche | Sep 2013 | 43 |
| NCT01483729Healthy Volunteer · New Zealand | 1 | Completed | Hoffmann-La Roche | Jan 2012 | 36 |
| NCT01418274Healthy Volunteer · United States | 1 | Completed | Hoffmann-La Roche | Sep 2011 | 20 |
| NCT01392755Healthy Volunteer · United States | 1 | Completed | Hoffmann-La Roche | Sep 2011 | 32 |
| NCT01389544Healthy Volunteer · United States | 1 | Completed | Hoffmann-La Roche | Jul 2011 | 18 |
| NCT01374802HIV Infections · Germany | 1 | Completed | Boehringer Ingelheim | Jul 2011 | 14 |
| NCT01335698HIV · United States, Argentina, Brazil and more | 3 | Completed | Bristol-Myers Squibb | Sep 10, 2014 | 160 |
| NCT01232127HIV · Germany, United Kingdom | 4 | Completed | Bristol-Myers Squibb | Jun 2011 | 25 |
| NCT01185860Hepatitis C, Chronic · France, New Zealand, Poland | 1 | Completed | Hoffmann-La Roche | Jan 2012 | 59 |
| NCT01185873Healthy Volunteer · United States, Czech Republic, Slovakia | 1 | Completed | Hoffmann-La Roche | Dec 2013 | 81 |
| NCT01099579HIV Infections · Brazil, Chile, Mexico and more | 3 | Completed | Bristol-Myers Squibb | Oct 4, 2012 | 82 |
| NCT00833482Acquired Immunodeficiency Syndrome · United States, Netherlands | 1 | Completed | Bristol-Myers Squibb | Jul 2010 | 185 |
| NCT00646776Antivirals/HIV · United States | 1 | Completed | Bristol-Myers Squibb | Aug 2008 | 85 |
| NCT00623597HIV Infections · Argentina, Spain, Thailand | 2 | Completed | Hoffmann-La Roche | Mar 2010 | 18 |
| NCT00552240HIV Infections · United States | 4 | Completed | Boehringer Ingelheim | Mar 2010 | 154 |
| NCT00530920HIV Infections · Germany, Italy, Spain | 2 | Completed | Boehringer Ingelheim | May 2008 | 85 |
| NCT00517192HIV Infections · United States, Bahamas, Belgium and more | 3 | Terminated | Boehringer Ingelheim | Sep 2008 | 40 |
| NCT00435929HIV Infections · United States, Canada, Puerto Rico | 1 | Completed | Hoffmann-La Roche | Nov 2009 | 16 |
| NCT00393328HIV Infections · United States | 1 | Completed | Bristol-Myers Squibb | Dec 2006 | 46 |
| NCT00384904HIV Infections · United States, United Kingdom | 4 | Completed | Bristol-Myers Squibb | Dec 2007 | 40 |
| NCT00365339HIV Infections · United States | 1 | Completed | Bristol-Myers Squibb | Jun 2006 | 40 |
How it is read
Names in the registry
- “Ritonavir”, 80 entries
- “ritonavir”, 35 entries
- “PF-07321332/ritonavir”, 9 entries
- “RTV”, 6 entries
- “ombitasvir/paritaprevir/ritonavir and dasabuvir”, 6 entries
Conditions, from the studies’ own filings
- HIV Infections, 51 studies
- Hepatitis C, 12 studies
- COVID-19, 11 studies
- Hepatitis C, Chronic, 11 studies
- Acquired Immunodeficiency Syndrome, 11 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.